Multicentric, Prospective, Non-Interventional Long-Term Registry Study to Describe the Safety and Importance of Gilenya (Fingolimod 05.mg) in the Treatment of Multiple Sclerosis Patients

Trial Profile

Multicentric, Prospective, Non-Interventional Long-Term Registry Study to Describe the Safety and Importance of Gilenya (Fingolimod 05.mg) in the Treatment of Multiple Sclerosis Patients

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 28 Oct 2017

At a glance

  • Drugs Fingolimod (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms PANGAEA
  • Sponsors Novartis
  • Most Recent Events

    • 28 Oct 2017 Interim results (Data cutoff January 2017, n=474) on safety and persistency for upto 5 years presented at the 7th Joint Congress of the European Committee for Treatment and Research in Multiple Sclerosis and Americas Committee for Treatment and Research in Multiple Sclerosis
    • 28 Oct 2017 First interim results of the 5 year analysis presented at the 7th Joint Congress of the European Committee for Treatment and Research in Multiple Sclerosis and Americas Committee for Treatment and Research in Multiple Sclerosis
    • 28 Oct 2017 Results of analysis comparing baseline data from PANGAEA and PANGAEA 2 trials to demonstrate a change in the profile of RRMS patients who switched to fingolimod between 2011-13 and 2015-17 presented at the 7th Joint Congress of the European Committee for Treatment and Research in Multiple Sclerosis and Americas Committee for Treatment and Research in Multiple Sclerosis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top